Cargando…

Whole-Body Radioiodine Effective Half-Life in Patients with Differentiated Thyroid Cancer

Background: Radioactive (131)I (RAI) therapy is used in patients with differentiated thyroid cancer (DTC) after total thyroidectomy for remnant ablation, adjuvant treatment or treatment of persistent disease. (131)I retention data, which are used to indicate the time at which a (131)I treated DTC pa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Klain, Michele, Nappi, Carmela, De Risi, Marina, Piscopo, Leandra, Volpe, Fabio, Manganelli, Mariarosaria, Caiazzo, Elisa, Bianco, Davide, Schlumberger, Martin, Cuocolo, Alberto
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8535104/ https://www.ncbi.nlm.nih.gov/pubmed/34679438 http://dx.doi.org/10.3390/diagnostics11101740

Ejemplares similares

Management of differentiated thyroid cancer through nuclear medicine facilities during Covid-19 emergency: the telemedicine challenge
por: Klain, Michele, et al.
Publicado: (2020)

Ablation rate after radioactive iodine therapy in patients with differentiated thyroid cancer at intermediate or high risk of recurrence: a systematic review and a meta-analysis
por: Klain, Michele, et al.
Publicado: (2021)

Prognostic value of 12-month response to therapy in pediatric patients with differentiated thyroid cancer
por: Zampella, Emilia, et al.
Publicado: (2023)

Intramedullary Spinal Cord Metastases from Differentiated Thyroid Cancer, a Case Report
por: Volpe, Fabio, et al.
Publicado: (2022)

Initial Testing of an Approximated, Fast Calculation Procedure for Personalized Dosimetry in Radionuclide Therapy Based on Planar Whole-Body Scan and Monte-Carlo Specific Dose Rates from the OpenDose Project
por: Bianco, Davide, et al.
Publicado: (2022)

Long-Term Prognostic Value of the Response to Therapy Assessed by Laboratory and Imaging Findings in Patients with Differentiated Thyroid Cancer
por: Klain, Michele, et al.
Publicado: (2021)

Efficacy of Empirical Radioiodine Therapy in Patients with Differentiated Thyroid Cancer and Elevated Serum Thyroglobulin without Evidence of Structural Disease: A Propensity Score Analysis
por: Piscopo, Leandra, et al.
Publicado: (2023)

Second Primary Malignancies in Patients with Differentiated Thyroid Cancer after Radionuclide Therapy: A Retrospective Single-Centre Study
por: Piscopo, Leandra, et al.
Publicado: (2022)

Emerging Role of Nuclear Medicine in Prostate Cancer: Current State and Future Perspectives
por: Volpe, Fabio, et al.
Publicado: (2023)

Prognostic Value of Hybrid PET/MR Imaging in Patients with Differentiated Thyroid Cancer
por: Piscopo, Leandra, et al.
Publicado: (2022)

Hyperfunctioning parathyroid gland and skeletal involvement on [(18)F]fluorocholine PET/CT: one look with two views
por: Nappi, Carmela, et al.
Publicado: (2022)

Diagnosis, Management and Theragnostic Approach of Gastro-Entero-Pancreatic Neuroendocrine Neoplasms
por: Piscopo, Leandra, et al.
Publicado: (2023)

Advances in Functional Imaging of Differentiated Thyroid Cancer
por: Klain, Michele, et al.
Publicado: (2021)

Combined bone scintigraphy and fluorocholine PET/computed tomography predicts response to radium-223 therapy in patients with prostate cancer
por: Klain, Michele, et al.
Publicado: (2021)

Cardiac hybrid imaging: novel tracers for novel targets
por: Ponsiglione, Andrea, et al.
Publicado: (2021)

Prognostic value of heart rate reserve in patients with suspected coronary artery disease undergoing stress myocardial perfusion imaging
por: Nappi, Carmela, et al.
Publicado: (2021)

Radioactive iodine-refractory differentiated thyroid cancer: an uncommon but challenging situation
por: Schmidt, Angelica, et al.
Publicado: (2017)

Role of serial cardiac (18)F-FDG PET-MRI in Anderson–Fabry disease: a pilot study
por: Nappi, Carmela, et al.
Publicado: (2021)

Safety and tolerability of sorafenib in patients with radioiodine-refractory thyroid cancer
por: Worden, Francis, et al.
Publicado: (2015)

The influence of thyroid hormone medication on intra-therapeutic half-life of (131)I during radioiodine therapy of solitary toxic thyroid nodules
por: Happel, Christian, et al.
Publicado: (2022)

2022 ETA Consensus Statement: What are the indications for post-surgical radioiodine therapy in differentiated thyroid cancer?
por: Pacini, Furio, et al.
Publicado: (2021)

False-positive radioiodine uptake after radioiodine treatment in differentiated thyroid cancer
por: Barbaro, Daniele, et al.
Publicado: (2023)

Incremental Value of Sestamibi SPECT/CT Over Dual-Phase Planar Scintigraphy in Patients With Primary Hyperparathyroidism and Inconclusive Ultrasound
por: Assante, Roberta, et al.
Publicado: (2019)

Focus on radioiodine-131 biokinetics: the influence of methylprednisolone on intratherapeutic effective half-life of (131)I during radioiodine therapy of Graves’ disease
por: Happel, C., et al.
Publicado: (2021)

Use of multikinase inhibitors/lenvatinib concomitant with radioiodine for the treatment of radioiodine refractory differentiated thyroid cancer
por: Herranz, Urbano Anido
Publicado: (2022)

Theophylline Increases the Uptake of Radioiodine by Mouse Thyroid
por: Lee, Jong Min, et al.
Publicado: (2004)

Radioiodine for thyroid cancer: sometimes, less is best
por: Padovani, Rosalia do Prado
Publicado: (2016)

Subgroup analysis of Japanese patients in a phase 3 study of lenvatinib in radioiodine‐refractory differentiated thyroid cancer
por: Kiyota, Naomi, et al.
Publicado: (2015)

Outcome of Patients With Differentiated Thyroid Cancer Treated With 131-Iodine on the Basis of a Detectable Serum Thyroglobulin Level After Initial Treatment
por: Klain, Michele, et al.
Publicado: (2019)

Radioiodine refractoriness score: A multivariable prediction model for postoperative radioiodine‐refractory differentiated thyroid carcinomas
por: Li, Genpeng, et al.
Publicado: (2018)

Redifferentiating Thyroid Cancer: Selumetinib-enhanced Radioiodine Uptake in Thyroid Cancer
por: Larson, Steven M., et al.
Publicado: (2017)

Predictors of Response and Survival to Multikinase Inhibitors in Radioiodine Resistant Differentiated Thyroid Cancer
por: Feola, Tiziana, et al.
Publicado: (2021)

Radioiodine Thyroid Ablation in Graves’ Hyperthyroidism: Merits and Pitfalls
por: Nwatsock, J. F., et al.
Publicado: (2012)

Oxidative stress and radioiodine treatment of differentiated thyroid cancer
por: Buczyńska, Angelika, et al.
Publicado: (2021)

Feasibility of Apatinib in Radioiodine-Refractory Differentiated Thyroid Carcinoma
por: Du, Wei, et al.
Publicado: (2022)

The EANM guideline on radioiodine therapy of benign thyroid disease
por: Campennì, Alfredo, et al.
Publicado: (2023)

Molecular Theranostics in Radioiodine-Refractory Differentiated Thyroid Cancer
por: Petranović Ovčariček, Petra, et al.
Publicado: (2023)

Incidental Spleen Cyst Mimicking Thyroid Carcinoma Metastasis: False-positive Uptake on Radioiodine Whole Body Scan
por: Genç, Mustafa, et al.
Publicado: (2023)

Defining Radioiodine-Refractory Differentiated Thyroid Cancer: Efficacy and Safety of Lenvatinib by Radioiodine-Refractory Criteria in the SELECT Trial
por: Kiyota, Naomi, et al.
Publicado: (2017)

Behind Traditional Semi-quantitative Scores of Myocardial Perfusion Imaging: An Eye on Niche Parameters
por: Nappi, Carmela, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_s4pso95uh7piuah3n1m58u0h3b